From the Immunopathology Section and ¶ Matrix
Metalloproteinase Unit, National Institute of Dental and Craniofacial
Research and the
Extracellular Matrix Pathology Section,
Laboratory of Pathology, NCI, National Institutes of Health, Bethesda,
Maryland 20892
Received for publication, October 19, 2000, and in revised form, March 19, 2001
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Membrane type 1-matrix
metalloproteinase (MT1-MMP)-mediated activation of MMP-2 is thought to
be important in the proteolysis of extracellular matrix in pathological
events in which monocytes/macrophages are found. Here we report on the
induction and regulation of human monocyte MT1-MMP and its role in
MMP-2 activation. Activation of monocytes by lipopolysaccharide
resulted in the induction of MT1-MMP mRNA and protein that was
suppressed by inhibitors of prostaglandin synthesis (indomethacin),
adenylyl cyclase (SQ 22536), and protein kinase A (Rp-cAMPs).
Suppression of MT1-MMP by indomethacin and SQ 22536 was reversed by
prostaglandin E2 and dibutyryl cyclic AMP,
respectively, demonstrating that induction of monocyte MT1-MMP is
regulated through a prostaglandin-cAMP pathway. Functional analysis
revealed that pro-MMP-2 in the supernatants from human bone marrow
stromal fibroblasts, normal male-derived fibroblasts and
melanoma cells (A2058) was converted to active MMP-2 when cultured with
activated but not control monocytes. Antibodies against MT1-MMP blocked
the activation of MMP-2. Tissue inhibitor of metalloproteinase-2
regulation of MMP-2 activation was shown through the addition of
varying amounts of recombinant tissue inhibitor of metalloproteinase-2
with pro-MMP-2 to MT1-MMP-expressing monocytes. These findings
demonstrate that activated monocytes express functionally active
MT1-MMP that may play a significant role in the activation of MMP-2
produced by other cells and as such influence developmental and
pathological conditions.
Extracellular tissue remodeling is critical in the
reorganization of connective tissue under both normal and pathological conditions including cell migration, angiogenesis, wound healing, inflammation, and invasion (1). Several matrix metalloproteinases (MMPs)1 take part in
extracellular matrix remodeling (2), but the molecular mechanism of how
these MMPs act is largely unknown (3). Critical events in the
physiologic mechanism of proteinase activation, which is regulated at
several levels, include cell type, site, and timing. MMPs are produced
as zymogens (pro-MMPs) that require proteolytic activation through the
elimination of the N-terminal propeptide (4). Once the enzymes are
active, they are susceptible to inhibition by a family of specific
tissue inhibitors, the tissue inhibitors of metalloproteinases (TIMPs).
TIMPs act to inhibit metalloproteinase activity by forming a complex
with active MMPs (5). The activation and inhibition of MMPs is tightly
regulated under normal physiological conditions; however, in a number
of pathological situations the strict regulatory mechanisms are lost, leading to tumor metastasis and connective tissue diseases such as arthritis.
The growing family of MMPs at present consists of more than 20 members
including the recently identified membrane type (MT1)-MMP. MMPs
subclassified as type IV collagenases/gelatinases include MMP-2 (72 kDa; gelatinase A) and MMP-9 (92 kDa; gelatinase B). These MMPs are
capable of degrading denatured and intact type IV collagen, a major
component of basement membranes, as well as other extracellular matrix
substrates. MMP-2 is unique in that the propeptide of this enzyme has
no apparent cleavage site for the proteinases that activate other MMPs.
MT1-MMP is believed to mediate the activation of MMP-2 on the cell
surface. The expression of MT1-MMP and activation of MMP-2 has been
associated with tumor invasion and metastasis (6, 7). Thus, production
of MT1-MMP is likely a major rate-limiting component of MMP-2
activation; therefore the MT1-MMP/MMP-2 system is an attractive
target for the prognosis and prevention of tumor progression.
Degradation of basement membranes and stromal extracellular matrix is
crucial for invasion and metastasis of malignant cells (8-10). The
expression of MMPs in tumors is regulated in a paracrine manner by
growth factors and cytokines secreted by tumor infiltrating inflammatory cells, as well as by tumor or stromal cells. Recent studies have suggested continuous cross-talk between tumor cells, stromal cells, and inflammatory cells during the invasion process. Monocytes/macrophages found at sites of extracellular remodeling have
been implicated in connective tissue destruction mediated through MMPs
(11-16). Because of the spatial distribution of tissue monocytes, also
known as tumor-associated macrophages, between invading tumors and
surrounding tumors, we have analyzed (a) the effect of
monocyte activation on the expression of MT1-MMP, (b) the
mechanism of monocyte MT1-MMP production, (c) the functional analysis of monocyte-derived MT1-MMP in activating MMP-2 secreted from
stromal cells, fibroblasts, or melanoma cells, and (d) the role of tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in
regulating the conversion or inhibition of MMP-2 to its active forms by
MT1-MMP-expressing monocytes.
Cells, Culture Conditions, and Reagents--
Human peripheral
blood monocytes were isolated by elutriation (17). Monocytes were
enriched >90% as determined by morphology, nonspecific esterase
staining, and flow cytometry. Purified monocytes were cultured in
serum-free Dulbecco's modified Eagle's medium (DMEM; BioWhittaker,
Walkersville, MD) supplemented with 2 mM L-glutamine (Mediatech, Washington, D. C.), and 10 µg/ml
gentamycin sulfate (BioWhittaker, Walkersville, MD). Indomethacin
(Sigma), SQ 22536 (Biomol), Rp-cAMPs (Biomol), PGE2
(Sigma), or Bt2cAMP (Sigma) were added as indicated.
Antibody against human MT1-MMP was obtained from Chemicon, Temecula,
CA. Human recombinant TIMP-2 was obtained from Fuji Chemical
Industries, Toyama, Japan. Progelatinase A (pro-MMP-2) was expressed in
a vaccinia virus expression system and purified as previously described
(18). Human bone marrow-derived fibroblasts (HBMFs; obtained from
Drs. Larry Fisher and Berthold Fohr, National Institute of Dental
and Craniofacial Research, NIH), normal male-derived fibroblasts
(NMDFs), and human melanoma cell line (A2058) (American Type Culture
Collection, Rockville, MD) were cultured in DMEM supplemented with 10%
fetal bovine serum (BioWhittaker, Walkersville, MD) on polystyrene
tissue culture dishes (Falcon 2059; Falcon Labware, Oxnard, CA). These
cells were then cultured in serum-free medium for 24 h, and the
media supernatants were added to control or LPS-treated monocytes. The results are representative of observations obtained in three or more
experiments using monocytes from different donors.
RNA Analysis--
Total RNA was isolated with TRIZOL reagent
(Life Technologies, Inc., Gaithersburg, MD) according to the
instructions of the manufacturer. MT1-MMP cDNA (a generous gift of
Dr. Motoharu Seiki) was used as a probe for identification of MT1-MMP
mRNA. MT1-MMP and GAPDH cDNA were labeled using Roche Molecular
Biochemicals random-primed DNA labeling kit. Prehybridization
and hybridization of both MT1-MMP and GAPDH probes were carried out at
65 °C in QuikHyb from Stratagene. The membranes were washed 4 times
in 2× SSC, 0.1% SDS for 20 min at 65 °C.
Cell Protein Isolation and Western Blot Analysis--
Cell
membranes were prepared from purified human monocytes treated under
various experimental conditions. The cells were washed in
phosphate-buffered saline containing protease inhibitors (10 µg/ml
aprotinin, 10 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor,
and 100 µg/ml 4-(2-aminoethyl)-benzene sulfonylfluoride-HCl; Calbiochem, San Diego, CA). The cell pellets were suspended in 250 mM sucrose solution containing protease inhibitors and
sonicated (Kontes ultrasonic cell disrupter; Vineland, NJ). The nuclear debris and unbroken cells were sedimented at 420 × g
for 15 min in a refrigerated microfuge. The resulting supernatant was
centrifuged at 20,800 × g for 30 min to pellet the
membrane proteins. The protein concentration of the membrane fraction
was determined by the Bradford assay (Bio-Rad Laboratories, Hercules,
CA). Equal amounts of protein were analyzed on 8-16% SDS
polyacrylamide Tris-glycine gels (Novex, San Diego, CA) under reducing
conditions. Western analysis was performed as described (19) using an
antibody against MT1-MMP (Chemicon International Inc., Temecula, CA).
The bands were visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).
Zymogram Analysis of MMP-2--
Conditioned media (20 µl) were
mixed with 5 µl of sample buffer to give a final concentration of 0.1 M Tris-HCl (pH 6.8), 2% (w/v) SDS, 0.02% bromphenol blue,
and 10% glycerol. The proteins were resolved on a discontinuous 10%
polyacrylamide Tris-glycine gel containing 0.1% (w/v) gelatin.
Following electrophoresis, the gels were equilibrated in 2.5% Triton
X-100 solution for 30 min at room temperature and subsequently
incubated at 37 °C in collagenase buffer (50 mM Tris-HCl
(pH 7.5)/200 mM NaCl/5 mM CaCl2) for 2 h. The gels were stained with Coomassie Blue (0.25%
Coomassie Blue, 45.4% methanol, and 9.2% glacial acetic acid) to
visualize the gelatinolytic bands corresponding to MMP-2.
Effect of LPS on Monocyte MT1-MMP RNA and Protein--
MT1-MMP is
known to have substrate specificity for diverse extracellular matrices
leading to physiological and pathological processes accompanying
tissue remodeling. In addition to its direct proteolysis of
extracellular matrix components, MT1-MMP plays a pivotal role in the
activation of pro-MMP-2 (6, 20). In this study we examined whether
activation of monocytes influenced the expression of MT1-MMP. For this
purpose, we treated monocytes with different concentrations of LPS as
indicated in Fig. 1. Northern analysis of
mRNA revealed that control monocytes had little or no detectable
levels of MT1-MMP mRNA (Fig. 1A). In contrast,
stimulation with LPS resulted in a dose-dependent induction
of MT1-MMP mRNA. Unlike other MMPs that are secreted as zymogens
and are activated in the extracellular compartment, MT1-MMP is
membrane-bound and is processed into an active enzyme prior to cell
surface localization (21, 22). To determine the levels of
membrane-associated MT1-MMP, Western analysis was performed using the
membrane preparations from control and LPS-treated monocytes. As shown
in Fig. 1B, LPS induced a dose-dependent
increase of MT1-MMP protein levels with no detectable MT1-MMP on
control monocytes.
Effect of PGE2 on Monocyte MT1-MMP Expression--
The
induction of MMPs in monocytes by agents such as concanavalin A, LPS,
or secreted protein, acidic and rich in cysteine, has been shown to
occur through a prostaglandin-dependent pathway (13, 16,
23-26). To determine whether monocyte MT1-MMP production is regulated
through this pathway, monocytes were pretreated with indomethacin for
1 h and then stimulated with LPS in the absence or presence of
PGE2. Similar to the data in Fig. 1, LPS stimulation resulted in an induction of monocyte MT1-MMP mRNA and protein whereas control cells had no detectable MT1-MMP (Fig.
2, A and B).
Indomethacin, at a concentration (10 Effect of Adenylyl Cyclase and Protein Kinase A Inhibitors on
MT1-MMP Induction--
PGE2 is known to stimulate adenylyl
cyclase, which results in the generation of cAMP and activation of
protein kinase A. To further establish that this was a major
pathway in the regulation of MT1-MMP in monocytes, inhibitors of
adenylyl cyclase and protein kinase A, SQ 22536, and Rp-cAMPs,
respectively, were tested for their effect on MT1-MMP induction. SQ
22536 caused a dose-dependent inhibition of MT1-MMP (Fig.
3). This suppression was reversed by
adding Bt2cAMP, thereby bypassing the requirement for
adenylyl cyclase in the generation of cAMP. Additional evidence for the involvement of cAMP and the subsequent increase in downstream signaling
proteins, such as protein kinase A, was the dose-dependent inhibitory effect of Rp-cAMPs, a protein kinase A inhibitor, on MT1-MMP
induction (Fig. 4, A and
B).
Effect of Monocytes on MMP-2 Activation from HBMF, NMDF, and
Cells--
To determine whether the monocytes could modulate MMP-2
activation, serum-deprived conditioned media from HBMF, NMDF, or
A2058 cells were added to the monocyte cultures in the absence or
presence of LPS. The incubation was carried out at 37 °C for 48 h. MMP-2, as in the case of the other MMPs, is initially secreted in a
latent form, which undergoes extracellular activation to yield an
intermediate and fully active form. Zymogram analysis can be used to
demonstrate pro, intermediate, and active forms. Because the incubation
of the zymogram with Triton X-100 involves conditions that renature the
MMP-2 proteins, all forms of MMP-2 exhibit gelatinolytic activity when
placed in collagenase buffer. Zymogram analysis of the supernatants revealed that although monocytes secrete significant amounts of MMP-9
when stimulated (data not shown) they do not produce detectable MMP-2
under these conditions (Fig. 5,
lanes 1 and 2). In contrast, the supernatants
from serum-starved HBMFs (lane 3), NMDFs (lane 6), and A2058 cells (lane 9) contained MMP-2 that was
primarily in the latent form. When supernatants from these cell lines
were added to monocytes that had been treated with LPS, the latent MMP-2 from these cell lines was converted to intermediate and fully
active forms (lanes 5, 8, and 11).
This was in contrast to control monocytes that failed to activate
MMP-2. These results demonstrate that activated monocytes may play an
important role in the conversion of latent MMP-2 produced by other
cells to the fully active form.
Effect of Antibody against MT1-MMP on MMP-2
Activation--
Although MT1-MMP production was detected in HBMF,
NMDF, and A2058 cells (data not shown), MMP-2 was not activated by
these cells. Therefore, we evaluated whether the significant activation of MMP-2 by monocytes was specifically related to the MT1-MMP on the
surface of the monocytes. Monocytes were cultured for 18 h with
LPS to induce MT1-MMP. The media was then replaced with serum-free
conditioned medium from HBMF cells, and an antibody against MT1-MMP or
normal rabbit IgG was added to some of the cultures at a dilution of
1:100. As shown in Fig. 6, antibodies against MT1-MMP inhibited (lane 7) the conversion of HBMF
latent or pro-MMP-2 to its intermediate and active forms by LPS-treated monocytes (lane5). In contrast, control normal rabbit IgG failed to
affect this conversion (lane 9). These findings confirm that MT1-MMP on monocytes is involved in the activation of MMP-2.
Effect of TIMP-2 on the Activation of MMP-2 by Monocytes--
It
has been hypothesized that a complex formed between MT1-MMP and TIMP-2
acts as a receptor for pro-MMP-2. The formation of this trimolecular
complex may be essential for the cell-mediated activation of pro-MMP-2,
which presumably interacts with a free adjacent MT1-MMP (27-29).
Immunoblot analysis with antibodies against TIMP-2 showed that
monocytes produced very low levels of TIMP-2, whereas considerable
amounts TIMP-2 were found in the media of the cell lines tested (data
not shown). These findings indicate that the low levels of TIMP-2
expressed by monocytes may allow free MT1-MMP to bind to the
MMP-2·TIMP-2 complex produced by other cell types, thus activating
MMP-2. To determine whether this was a possibility, various
concentrations of human recombinant TIMP-2 were added to the monocytes.
As shown in Fig. 7, activation of HBMF
MMP-2 by LPS-treated monocytes was inhibited in a
dose-dependent manner with increasing concentrations of
recombinant TIMP-2 (1 to 100 ng/ml). These results suggest that the
conversion of pro-MMP-2 to the active form was inhibited when all of
the free MT1-MMP on the monocyte surface was bound to TIMP-2. To
determine whether this hypothesis was correct and that TIMP-2 is also
involved in the activation of MMP-2, various concentrations of
human recombinant TIMP-2 were added with purified-recombinant
pro-MMP-2 (5 nM) to control and LPS-activated monocytes.
Zymogram analysis revealed that a TIMP-2 dose-dependent
activation of MMP-2 occurred in LPS-stimulated monocytes but not
control cells (Fig. 8). Maximal
activation was evident at approximately equal molar concentrations (5 nM) of TIMP-2 and pro-MMP-2. TIMP-2 at higher
concentrations (15 to 20 nM) inhibited the activation of
MMP-2. In contrast to monocytes, similar experiments carried out with
human skin fibroblasts failed to result in activation of the pro-MMP-2
(data not shown). These findings support the concept that activation of
MMP-2 involves binding of the MMP2·TIMP-2 complex to MT1-MMP with
subsequent activation by free adjacent MT1-MMPs.
The present work demonstrates that activation of monocytes results
in the expression of mRNA for MT1-MMP with the subsequent localization of the protein on the surface of the cell. It has been
reported that monocytes secrete a number of MMPs in response to various
stimulants (12, 30-32). The induction of these MMPs is thought to
occur at the pre-translational level. Consistent with these findings,
we have observed an increase in mRNA and protein levels of MT1-MMP
in LPS-stimulated monocytes. Examination of MT1-MMP revealed that only
stimulated monocytes expressed mRNA for MT1-MMP and had MT1-MMP on
their membrane surface.
MMPs have been associated with several pathological conditions such as
chronic inflammatory lesions and cancer metastasis (33-35). Therefore,
regulation of signal transduction events that are associated with the
production of inflammatory mediators, such as MMPs, has been of
considerable interest. A PGE2-cAMP-dependent pathway leading to the production of MMP-1, MMP-9, and MMP-7
(matrilysin) by activated monocytes has been demonstrated previously
(13, 16, 23-26). In the present study, we have demonstrated that LPS induces monocyte MT1-MMP and that the signaling pathway for MT1-MMP synthesis involves, in large part, a
PGE2-dependent mechanism. This was demonstrated
by the ability of exogenous PGE2 to reverse indomethacin-mediated inhibition of MT1-MMP. Additional evidence for
the involvement of cAMP in this pathway is the suppression of MT1-MMP
by adenylyl cyclase or protein kinase A inhibitors. Regulation of
MT1-MMP through a PGE2-dependent mechanism has
also been reported for the induction of MT1-MMP in fibroblasts
stimulated with monensin (36). In the same study, the induction of
fibroblast MT1-MMP by monensin was also inhibited by indomethacin, an
effect that was reversed by PGE2.
Many lines of evidence link increased MMP levels with tumor
invasiveness and metastatic potential (37-43). It is hypothesized that
basement membrane degrading MMP-2 is involved in the invasion and
metastasis of malignant tumors and in the angiogenesis required for
tumor growth (35, 37). In many instances, enhanced MMP-2 production has
been traced to the malignant cells themselves (37, 40). However, it has
also been shown that some tumors produce little MMP-2, and the
major source of this enzyme is from stromal cells and fibroblasts (8,
9). Regardless of the source of MMP-2, activation of this enzyme is
critical for its proteolytic activity and indicates the invasive
phenotype of the tumors. In the present study, we demonstrate that the
MT1-MMP on activated monocytes may have an important role in the
activation of MMP-2 produced by other cells. Zymogram analysis of
conditioned media from control or activated monocytes failed to detect
MMP-2. In contrast, the conditioned media collected from HBMF, NMDF, or A2058 cells contained substantial levels of latent MMP-2, which was
converted to its intermediate and fully active forms when cultured with
activated monocytes. Furthermore, the activation of MMP-2 was blocked
by antibodies against MT1-MMP. These results suggest that communication
between monocytes producing MT1-MMP with either tumor or
tumor-associated cells expressing MMP-2 is essential for the activation
of MMP-2, leading to the metastatic potential of the tumor cell. Our
finding that only activated but not control monocytes were able to
convert pro-MMP-2 to its active form indicates the significance of
activated monocytes in this process. Although we have used LPS to
stimulate monocytes in vivo it is likely that stimulatory
molecules, such as cytokines, cancer cell-associated factors, or
extracellular matrix components may exert the same effect.
Several studies have suggested activation of MMP-2 through physical
cell-cell contact (27, 44, 45). Contrary to these reports, we have
demonstrated that soluble pro-MMP-2 secreted by HBMF, NMDF, or A2058
cells into the conditioned medium could still be activated when
incubated with monocyte MT1-MMP. Pro-MMP-2, unlike other MMPs, is
usually found complexed with endogenous TIMP-2 (11, 46, 47). The
presence of inhibitor bound to the latent enzyme suggests that the
inhibitor may play some additional role. Indeed, several recent reports
have suggested that the formation of a complex among pro-MMP-2, TIMP-2,
and MT1-MMP is needed for MMP-2 activation and that TIMP-2 levels are
critical in MMP-2 activation by MT1-MMP (27, 48-50). Based on these
studies, it has been hypothesized that two molecules of MT1-MMP are
required for activation of MMP-2. One of these molecules binds a
complex of TIMP-2·MMP-2 whereas an adjacent free MT1-MMP activates
MMP-2 (for review see Ref. 22). This model of activation may
explain the possible mechanism of activation of pro-MMP-2 in our study. Although we observed substantial amounts of MT1-MMP and TIMP-2 protein
on HBMF, NMDF, and A2058 cells (data not shown) these cells failed to
activate the MMP-2. A possible explanation for this finding is that the
excess TIMP-2 produced by these cells binds to all or most of the
MT1-MMP on the surface of these cells, thus preventing activation of
MMP-2 by MT1-MMP. In contrast, monocytes produce very little TIMP-2 or
MMP-2. As a result, there is sufficient free MT1-MMP on the monocyte
cell surface to bind the TIMP-2·MMP-2 complex derived from other
cells with enough remaining free MT1-MMP to activate MMP-2. Thus, the
ratio of TIMP-2 and MT1-MMP is critical for optimum activation of
MMP-2. This hypothesis is supported by data shown in Figs. 7 and 8. The
data in Fig. 7 demonstrate that excess TIMP-2 does indeed inhibit the
activation of MMP-2 from HBMF by monocytes. In Fig. 8, the addition of
human recombinant TIMP-2 with purified-recombinant pro-MMP-2 to
LPS-stimulated monocytes demonstrated that TIMP-2 is required for
activation of pro-MMP-2. Moreover, the optimal activation occurred when
pro-MMP-2 and TIMP-2 were in equal molar concentrations. However, when
TIMP-2 was in significant excess the activation of MMP-2 was inhibited,
presumably because of the saturation of the available MT1-MMP molecules
by TIMP-2.
In summary, we have demonstrated that activated monocytes produce
functionally active MT1-MMP through a
prostaglandin-cAMPdependent mechanism. The monocyte-derived
MT1-MMP is involved in the activation of MMP-2 produced by other cells.
These results suggest that the in vivo interaction between
monocytes and MMP-2-secreting cells may play a crucial role in the
regulation of normal developmental processes and disease states, such
as tumor invasion. Thus, defining the mechanism and developing
therapeutic interventions involved in the regulation of monocyte
MT1-MMP may be important in controlling the immunopathology associated
with various diseases.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
View larger version (52K):
[in a new window]
Fig. 1.
Effect of LPS on monocyte MT1-MMP
expression. Human peripheral blood monocytes prepared by
elutriation were cultured (20 × 106 cells per 4 ml of
DMEM) for 18 or 48 h in the absence or presence of LPS. Total
cellular RNA was prepared from monocytes treated with the indicated
dose of LPS for 18 h and analyzed for MT1-MMP mRNA and GAPDH
as a reference for equal loading (panel A). Panel
B shows the immunoblot analysis of MT1-MMP protein expression.
Cell membranes were prepared from monocytes treated with the indicated
doses of LPS for 48 h. An equal amount of membrane protein (100 µg) from each sample was analyzed in a 10% SDS polyacrylamide gel
electrophoresis. Western analysis was performed using an antibody
against MT1-MMP. The protein bands were visualized by enhanced
chemiluminescence detection.
6 M) that
significantly inhibits the induction of monocyte PGE2 by
LPS, suppressed the levels of MT1-MMP mRNA and protein in
stimulated cells. The addition of PGE2 reversed the
indomethacin-mediated suppression of MT1-MMP mRNA and protein.
These findings demonstrate that LPS induces MT1-MMP, in large part,
through a prostaglandindependent mechanism. Moreover, this
induction requires a primary signal, in addition to PGE2,
because PGE2 in the absence of LPS failed to induce MT1-MMP
as shown either at the mRNA or protein level.
View larger version (32K):
[in a new window]
Fig. 2.
Prostaglandin-dependent
regulation of monocyte MT1-MMP. Purified monocytes were pretreated
with indomethacin (10 6 M) for 1 h, and
LPS (100 ng/ml) and PGE2 were added to some of the cultures
as indicated. Panel A is representative of the Northern
analysis of MT1-MMP. The total RNA was prepared from monocytes after
18 h of culture and subjected to mRNA analysis for MT1-MMP and
GAPDH as described under "Materials and Methods." Panel
B shows the Western blot of monocyte membranes (100 µg/lane),
collected after 48 h of culture, using an antibody against
MT1-MMP.
View larger version (25K):
[in a new window]
Fig. 3.
Effect of SQ 22536 on monocyte MT1-MMP.
Purified monocytes (20 × 106 per 4 ml of DMEM) were
pretreated with SQ 22536, an adenylyl cyclase inhibitor, at the
indicated concentrations for 1 h. LPS (100 ng/ml) and
Bt2cAMP were than added as indicated. Monocyte membranes
were collected after 48 h, and 100 µg of protein was loaded in
each lane and analyzed by Western blot with an antibody against
MT1-MMP.
View larger version (62K):
[in a new window]
Fig. 4.
Effect of Rp-cAMPs on monocyte MT1-MMP.
Purified monocytes were incubated with the indicated concentrations of
Rp-cAMPs, a protein kinase A inhibitor, for 1 h. LPS (100 ng/ml)
was then added as indicated. Panel A represents the Northern
analysis of MT1-MMP. The total RNA was prepared from monocytes after
18 h of culture and analyzed for mRNA of MT1-MMP and GAPDH as
described under "Materials and Methods." Panel B shows
the Western blot of monocyte membranes (100 µg/lane),
collected after 48 h of culture, using an antibody against
MT1-MMP.
View larger version (27K):
[in a new window]
Fig. 5.
Activation of MMP-2 from cell lines by human
monocytes. Monocytes (5 × 106 in 0.5 ml/well)
were cultured for 18 h in the presence or absence
(Control) of LPS and then serum-free conditioned media (0.5 ml) from HBMF, NMDF, or A2058 cells were added to the monocyte cultures
or cell-free culture wells ( ). Media were harvested 48 h later,
and 20 µl of sample was subjected to zymogram analysis. The bands
corresponding to P, I, and F are the
pro, intermediate, and fully active forms respectively, of MMP-2.
View larger version (30K):
[in a new window]
Fig. 6.
Human monocyte MT1-MMP mediates MMP-2
activation. Freshly prepared human peripheral blood monocytes were
cultured at 5 × 106 cells/ml of DMEM. The cultures
were incubated either in the absence or presence of LPS (100 ng/ml).
After 18 h the culture medium was replaced with serum-free
conditioned medium from HBMF cells, and an antibody against MT1-MMP or
IgG from normal rabbit serum was added to some of the cultures. The
culture incubation was carried out for an additional 48 h. The
samples were subjected to zymogram analysis, and the pro
(P), intermediate (I), and fully active
(F) forms of MMP-2 were visualized after Coomassie Blue
staining.
View larger version (26K):
[in a new window]
Fig. 7.
Inhibition of HBMF MMP-2 activation by
TIMP-2. Monocytes (5 × 106/ml) were cultured
with or without LPS- and HBMF-conditioned medium, as described in Fig.
6, in the presence or absence of TIMP-2 at various concentrations as
indicated. The samples were subjected to gelatin zymography, and the
pro (P), intermediate (I), and fully active
(F) forms of MMP-2 were visualized after Coomassie Blue
staining.
View larger version (27K):
[in a new window]
Fig. 8.
Requirement for TIMP-2 in the activation of
MMP-2 by human monocytes. Monocytes (5 × 106/ml)
were cultured in the presence or absence (Control) of LPS
(100 µg/ml) for 18 h and then human recombinant TIMP-2 and
purified-recombinant pro-MMP-2 were added as indicated. The
supernatants were harvested after an additional 24 h and analyzed
by gelatin zymography. The pro (P), intermediate
(I), and fully active (F) forms of MMP-2 were
visualized after Coomassie Blue staining.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]() |
FOOTNOTES |
---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Present address: SRA International, Inc., Rockville, MD 20852.
** To whom correspondence should be addressed: Immunopathology Section, 30 Convent Dr., National Institute of Dental and Craniofacial Research, NIH, Bldg. 30, Rm. 325, Bethesda, MD 20892. Tel.: 301-496-9219; Fax: 301-402-1064; E-mail: lwahl@dir.nidcr.nih.gov.
Published, JBC Papers in Press, March 20, 2001, DOI 10.1074/jbc.M009562200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: MMP(s), matrix metalloproteinase(s); MT, membrane-type; TIMP(s), tissue inhibitors of metalloproteinases; LPS, lipopolysaccharide; PGE2, prostaglandin E2; DMEM, Dulbecco's modified Eagle's medium; Bt2cAMP, dibutyryl cyclic AMP; HBMF(s), human bone marrow-derived fibroblasts; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TIMP-2, tissue inhibitor of matrix metalloproteinases-2; NMDF, normal male-derived fibroblasts.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Deryugina, E. I., Bourdon, M. A., Reisfeld, R. A., and Strongin, A. (1998) Cancer Res. 58, 3743-3750[Abstract] |
2. | Birkedal-Hansen, H. (1995) Curr. Opin. Cell Biol. 7, 728-735[CrossRef][Medline] [Order article via Infotrieve] |
3. | Werb, Z., Ashkenas, J., MacAuley, A., and Wiesen, J. F. (1996) Braz. J. Med. Biol. Res. 29, 1087-1097[Medline] [Order article via Infotrieve] |
4. | Van Wart, H. E., and Birkedal-Hansen, H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5578-5582[Abstract] |
5. |
Chambers, A. F.,
and Matrisian, L. M.
(1997)
J. Natl. Cancer Inst.
89,
1260-1270 |
6. | Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) Nature 370, 61-65[CrossRef][Medline] [Order article via Infotrieve] |
7. | Yamamoto, M., Mohanam, S., Sawaya, R., Fuller, G. N., Seiki, M., Sato, H., Gokaslan, Z. L., Liotta, L. A., Nicolson, G. L., and Rao, J. S. (1996) Cancer Res. 56, 384-392[Abstract] |
8. | Pyke, C., Ralfkiaer, E., Tryggvason, K., and Dano, K. (1993) Am. J. Pathol. 142, 359-365[Abstract] |
9. | Kuranami, M., Cohen, A. M., and Guillem, J. G. (1994) Surgical Forum 45, 551-553 |
10. | Swallow, C. J., Murray, M. P., and Guillem, J. G. (1996) Clin. Exp. Metastasis 14, 3-11[Medline] [Order article via Infotrieve] |
11. |
Wilhelm, S. M.,
Collier, I. E.,
Marmer, B. L.,
Eisen, A. Z.,
Grant, G. A.,
and Goldberg, G. I.
(1989)
J. Biol. Chem.
264,
17213-17221 |
12. | Welgus, H. G., Campbell, E. J., Cury, J. D., Eisen, A. Z., Senior, R. M., Wilhelm, S. M., and Goldberg, G. I. (1990) J. Clin. Invest. 86, 1496-1502[Medline] [Order article via Infotrieve] |
13. | Wahl, L. M., and Lampel, L. L. (1987) Cell. Immunol. 105, 411-422[Medline] [Order article via Infotrieve] |
14. | Wahl, L. M., Shankavaram, U., and Zhang, Y. (1997) Transpl. Immunol. 5, 173-176[CrossRef][Medline] [Order article via Infotrieve] |
15. | Mertz, P. M., Corcoran, M. L., McCluskey, K. M., Zhang, Y., Wong, H. L., Lotze, M. T., DeWitt, D. L., Wahl, S. M., and Wahl, L. M. (1996) Cell. Immunol. 173, 252-260[CrossRef][Medline] [Order article via Infotrieve] |
16. | Shankavaram, U. T., DeWitt, D. L., Funk, S. E., Sage, E. H., and Wahl, L. M. (1997) J. Cell. Physiol. 173, 327-334[CrossRef][Medline] [Order article via Infotrieve] |
17. | Wahl, L. M., and Smith, P. (1991) in Current Protocols in Immunology (Coligan, J. E. , Kruisbeek, A. M. , Margulies, D. H. , Shevach, E. M. , and Strober, W., eds) , pp. 7.6.1-7.6.6, John Wiley & Sons, Inc., New York |
18. |
Fridman, R.,
Fuerst, T. R.,
Bird, R. E.,
Hoyhtya, M.,
Oelkuct, M.,
Kraus, S.,
Komarek, D.,
Liotta, L. A.,
Berman, M. L.,
and Stetler-Stevenson, W. G.
(1992)
J. Biol. Chem.
267,
15398-15405 |
19. | Shankavaram, U. T., DeWitt, D. L., and Wahl, L. M. (1998) J. Leukocyte Biol. 64, 221-227[Abstract] |
20. | Nagase, H. (1998) Cell Res. 8, 179-186[Medline] [Order article via Infotrieve] |
21. | Hiraoka, N., Allen, E., Apel, I. J., Gyerko, M. R., and Weiss, S. J. (1998) Cell 95, 365-377[Medline] [Order article via Infotrieve] |
22. | Werb, Z. (1997) Cell 91, 439-442[Medline] [Order article via Infotrieve] |
23. | Wahl, L. M., Olsen, C. E., Sandberg, A. L., and Mergenhagen, S. E. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 4955-4958[Abstract] |
24. | Corcoran, M. L., Stetler-Stevenson, W. G., DeWitt, D. L., and Wahl, L. M. (1994) Arch. Biochem. Biophys. 310, 481-488[CrossRef][Medline] [Order article via Infotrieve] |
25. |
Shapiro, S. D.,
Kobayashi, D. K.,
Pentland, A. P.,
and Welgus, H. G.
(1993)
J. Biol. Chem.
268,
8170-8175 |
26. |
McCarthy, J. B.,
Wahl, S. M.,
Rees, J. C.,
Olsen, C. E.,
Sandberg, L.,
and Wahl, L. M.
(1980)
J. Immunol.
124,
2405-2409 |
27. |
Strongin, A. Y.,
Marmer, B. L.,
Grant, G. A.,
and Goldberg, G. I.
(1993)
J. Biol. Chem.
268,
14033-14039 |
28. |
Strongin, A. Y.,
Collier, I.,
Bannikov, G.,
Marmer, B. L.,
Grant, G. A.,
and Goldberg, G. I.
(1995)
J. Biol. Chem.
270,
5331-5338 |
29. |
Kinoshita, T.,
Sato, H.,
Okada, A.,
Ohuchi, E.,
Imai, K.,
Okada, Y.,
and Seiki, M.
(1998)
J. Biol. Chem.
273,
16098-16103 |
30. |
Campbell, E. J.,
Cury, J. D.,
Shapiro, S. D.,
Goldberg, G. I.,
and Welgus, H. G.
(1991)
J. Immunol.
146,
1286-1293 |
31. |
Watanabe, H.,
Nakanishi, I.,
Yamashita, K.,
Hayakawa, T.,
and Okada, Y.
(1993)
J. Cell Sci.
104,
991-999 |
32. |
Zhang, Y.,
McCluskey, K.,
Fujii, K.,
and Wahl, L. M.
(1998)
J. Immunol.
161,
3071-3076 |
33. | Brinckerhoff, C. E. (1992) Crit. Rev. Eukaryotic Gene Expression 2, 145-164[Medline] [Order article via Infotrieve] |
34. | Wahl, L. M., Wahl, S. M., Mergenhagen, S. E., and Martin, G. R. (1974) Proc. Natl. Acad. Sci. U. S. A. 71, 3598-3601[Abstract] |
35. | Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. (1991) Cell 64, 327-336[Medline] [Order article via Infotrieve] |
36. | Li, L., Akers, K., Eisen, A. Z., and Seltzer, J. L. (1997) Exp. Cell Res. 232, 322-330[CrossRef][Medline] [Order article via Infotrieve] |
37. | Matrisian, L. M. (1992) Bioessays 14, 455-463[Medline] [Order article via Infotrieve] |
38. | Cottam, D. W., Rennie, I. G., Woods, K., Parsons, M. A., Bunning, R. A., and Rees, R. C. (1992) Invest. Ophthalmol. Visual Sci. 33, 1923-1927[Abstract] |
39. | Murphy, G., Reynolds, J. J., and Hembry, R. M. (1989) Int. J. Cancer 44, 757-760[Medline] [Order article via Infotrieve] |
40. | Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. (1980) Nature 284, 67-68[Medline] [Order article via Infotrieve] |
41. | Nakajima, M., Welch, D. R., Belloni, P. N., and Nicolson, G. L. (1987) Cancer Res. 47, 4869-4876[Abstract] |
42. | Bernhard, E. J., Gruber, S. B., and Muschel, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4293-4297[Abstract] |
43. | Baker, T., Tickle, S., Wasan, H., Docherty, A., Isenberg, D., and Waxman, J. (1994) Br. J. Cancer 70, 506-512[Medline] [Order article via Infotrieve] |
44. | Murphy, G., Willenbrock, F., Ward, R. V., Cockett, M. I., Eaton, D., and Docherty, A. J. (1992) Biochem. J. 283, 637-641[Medline] [Order article via Infotrieve] |
45. | Brown, P. D., Levy, A. T., Margulies, I. M., Liotta, L. A., and Stetler-Stevenson, W. G. (1990) Cancer Res. 50, 6184-6191[Abstract] |
46. | Goldberg, G. I., Marmer, B. L., Grant, G. A., Eisen, A. Z., Wilhelm, A., and He, C. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8207-8211[Abstract] |
47. |
Stetler-Stevenson, W. G.,
Krutzsch, H. C.,
and Liotta, L. A.
(1989)
J. Biol. Chem.
264,
17374-17378 |
48. | Kleiner, D. E., Jr., Tuuttila, A., Tryggvason, K., and Stetler-Stevenson, W. G. (1993) Biochemistry 32, 1583-1592[Medline] [Order article via Infotrieve] |
49. | Ward, R. V., Atkinson, S. J., Slocombe, P. M., Docherty, A. J., Reynolds, J. J., and Murphy, G. (1991) Biochim. Biophys. Acta 1079, 242-246[Medline] [Order article via Infotrieve] |
50. |
Hernandez-Barrantes, S.,
Toth, M.,
Bernardo, M. M.,
Yurkova, M.,
Gervasi, D. C.,
Raz, Y.,
Sang, Q. A.,
and Fridman, R.
(2000)
J. Biol. Chem.
275,
12080-12089 |